Lung Functions Among Patients with Pulmonary Tuberculosis in Dar Es Salaam - a Cross-sectional Study

Overview

Journal BMC Pulm Med

Publisher Biomed Central

Specialty Pulmonary Medicine

Date 2016 Apr 25

PMID 27107713

Citations 27

Authors

Mohamed Manji

Grace Shayo

Simon Mamuya

Rose Mpembeni

Ahmed Jusabani

Ferdinand Mugusi

Affiliations

Soon will be listed here.

Abstract

Background: Approximately 40-60 % of patients remain sufferers of sequela of obstructive, restrictive or mixed patterns of lung disease despite treatment for pulmonary tuberculosis (PTB). The prevalence of these abnormalities in Tanzania remains unknown.

Methods: A descriptive cross-sectional study was carried out among 501 patients with PTB who had completed at least 20 weeks of treatment. These underwent spirometry and their lung functions were classified as normal or abnormal (obstructive, restrictive or mixed). Logistic regression models were used to explore factors associated with abnormal lung functions.

Results: Abnormal lung functions were present in 371 (74 %) patients. There were 210 (42 %) patients with obstructive, 65 (13 %) patients with restrictive and 96 (19 %) patients with mixed patterns respectively. Significant factors associated with abnormal lung functions included recurrent PTB (Adj OR 2.8, CI 1.274 - 6.106), Human Immunodeficiency Virus (HIV) negative status (Adj OR 1.7, CI 1.055 - 2.583), age more than 40 years (Adj OR 1.7, CI 1.080 - 2.804) and male sex (Adj OR 1.7, CI 1.123 - 2.614).

Conclusion: The prevalence of abnormal lung functions is high and it is associated with male sex, age older than 40 years, recurrent PTB and HIV negative status.

Citing Articles

Sequelae of Immunocompromised Host Pneumonia.

Salwen B, Mascarenhas E, Horne D, Crothers K, Zifodya J Clin Chest Med. 2025; 46(1):49-60.

PMID: 39890292 PMC: 11790256. DOI: 10.1016/j.ccm.2024.10.004.

Risk factors associated with post-tuberculosis sequelae: a systematic review and meta-analysis.

Akalu T, Clements A, Liyew A, Gilmour B, Murray M, Alene K EClinicalMedicine. 2024; 77:102898.

PMID: 39502524 PMC: 11535315. DOI: 10.1016/j.eclinm.2024.102898.

Implementation of spirometry screening for post-tuberculosis lung disease (PTLD) among adolescents and adults enrolled within the National Tuberculosis Control Program of Carmelo Hospital in Chókwè District, Mozambique: A hybrid type III....

Myers H, Chongo B, Zifodya J, Zacaria I, Machava E, Simango A BMC Pulm Med. 2024; 24(1):502.

PMID: 39390443 PMC: 11465890. DOI: 10.1186/s12890-024-03329-7.

Finding the missing men with tuberculosis: a participatory approach to identify priority interventions in Uganda.

Nidoi J, Pulford J, Wingfield T, Thomson R, Rachael T, Ringwald B Health Policy Plan. 2024; 40(1):1-12.

PMID: 39215966 PMC: 11724639. DOI: 10.1093/heapol/czae087.

Inhibition of host PARP1 contributes to the anti-inflammatory and antitubercular activity of pyrazinamide.

Krug S, Gupta M, Kumar P, Feller L, Ihms E, Kang B Nat Commun. 2023; 14(1):8161.

PMID: 38071218 PMC: 10710439. DOI: 10.1038/s41467-023-43937-1.

References

Ferguson G, Enright P, Buist A, Higgins M . Office spirometry for lung health assessment in adults: A consensus statement from the National Lung Health Education Program. Chest. 2000; 117(4):1146-61. DOI: 10.1378/chest.117.4.1146. View

Pasipanodya J, Miller T, Vecino M, Munguia G, Garmon R, Bae S . Pulmonary impairment after tuberculosis. Chest. 2007; 131(6):1817-24. DOI: 10.1378/chest.06-2949. View

Pauwels R, Buist A, Calverley P, Jenkins C, Hurd S . Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001; 163(5):1256-76. DOI: 10.1164/ajrccm.163.5.2101039. View

BIRATH G, Caro J, MALMBERG R, SIMONSSON B . Airways obstruction in pulmonary tuberculosis. Scand J Respir Dis. 1966; 47(1):27-36. View

Calderon E, Rivero L, Respaldiza N, Morilla R, Montes-Cano M, Friaza V . Systemic inflammation in patients with chronic obstructive pulmonary disease who are colonized with Pneumocystis jiroveci. Clin Infect Dis. 2007; 45(2):e17-9. DOI: 10.1086/518989. View

Vargha G . Fifteen year follow-up of lung function in obstructive and non-obstructive pulmonary tuberculosis. Acta Med Hung. 1983; 40(4):271-6. View

Barr R, Stemple K, Mesia-Vela S, Basner R, Derk S, Henneberger P . Reproducibility and validity of a handheld spirometer. Respir Care. 2008; 53(4):433-41. PMC: 3595551. View

Weis S, Miller T, Hilsenrath P, Moonan P . Comprehensive cost description of tuberculosis care. Int J Tuberc Lung Dis. 2005; 9(4):467-8. View

Lee S, Kim Y, Kim D, Oh Y, Lee S . The risk of obstructive lung disease by previous pulmonary tuberculosis in a country with intermediate burden of tuberculosis. J Korean Med Sci. 2011; 26(2):268-73. PMC: 3031013. DOI: 10.3346/jkms.2011.26.2.268. View

10.

Walters J, Wood-Baker R, Walls J, Johns D . Stability of the EasyOne ultrasonic spirometer for use in general practice. Respirology. 2006; 11(3):306-10. DOI: 10.1111/j.1440-1843.2006.00842.x. View

11.

Skloot G, Edwards N, Enright P . Four-year calibration stability of the EasyOne portable spirometer. Respir Care. 2010; 55(7):873-7. View

12.

Willcox P, Ferguson A . Chronic obstructive airways disease following treated pulmonary tuberculosis. Respir Med. 1989; 83(3):195-8. DOI: 10.1016/s0954-6111(89)80031-9. View

13.

Prescott E, Lange P, Vestbo J . Socioeconomic status, lung function and admission to hospital for COPD: results from the Copenhagen City Heart Study. Eur Respir J. 1999; 13(5):1109-14. DOI: 10.1034/j.1399-3003.1999.13e28.x. View

14.

Stenton C . The MRC breathlessness scale. Occup Med (Lond). 2008; 58(3):226-7. DOI: 10.1093/occmed/kqm162. View

15.

Miller T, McNabb S, Hilsenrath P, Pasipanodya J, Weis S . Personal and societal health quality lost to tuberculosis. PLoS One. 2009; 4(4):e5080. PMC: 2660416. DOI: 10.1371/journal.pone.0005080. View

16.

Plit M, Anderson R, Van Rensburg C, Page-Shipp L, Blott J, Fresen J . Influence of antimicrobial chemotherapy on spirometric parameters and pro-inflammatory indices in severe pulmonary tuberculosis. Eur Respir J. 1998; 12(2):351-6. DOI: 10.1183/09031936.98.12020351. View

17.

Konietzko N, CARTON R, LEROY E . Causes of death in patients with bronchiectasis. Am Rev Respir Dis. 1969; 100(6):852-8. DOI: 10.1164/arrd.1969.100.6.852. View

18.

Shoemark A, Ozerovitch L, Wilson R . Aetiology in adult patients with bronchiectasis. Respir Med. 2007; 101(6):1163-70. DOI: 10.1016/j.rmed.2006.11.008. View

19.

Pasteur M, Helliwell S, Houghton S, Webb S, Foweraker J, Coulden R . An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med. 2000; 162(4 Pt 1):1277-84. DOI: 10.1164/ajrccm.162.4.9906120. View

20.

Chavasse R, Johnson P, Francis J, Balfour-Lynn I, Rosenthal M, Bush A . To clip or not to clip? Noseclips for spirometry. Eur Respir J. 2003; 21(5):876-8. DOI: 10.1183/09031936.03.00048303. View